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The Induction of Bone Formation:
The Translation Enigma
Roland M. Klar*
Laboratory of Biomechanics and Experimental Orthopaedics, Department of Orthopaedic Surgery, Physical Medicine and
Rehabilitation, University Hospital of Munich (LMU), Munich, Germany
A paradigmatic shift in the way of thinking is what bone tissue engineering science
requires to decrypt the translation conundrum from animal models into human. The
deductive work of Urist (1965), who discerned the principle of bone induction from the
pioneering works of Senn, Huggins, Lacroix, Levander, and other bone regenerative
scientists, provided the basis that has assisted future bone tissue regenerative scientists
to extend the bone tissue engineering field and its potential uses for bone regenerative
medicine in humans. However, major challenges remain that are preventing the formation
of bone by induction clinically. Growing experimental evidence is indicating that bone
inductive studies are non-translatable from animal models into a clinical environment.
This is preventing bone tissue engineering from reaching the next phase in development.
Countless studies are trying to discern how the formation of bone by induction functions
mechanistically, so as to try and solve this enigmatic problem. However, are the correct
questions being asked?Why do bone inductive animal studies not translate into humans?
Why do bone induction principles not yield the same extent of bone formation as an
autogenous bone graft?What are bone tissue engineering scientists missing? By critically
re-assessing the past and present discoveries of the bone induction field, this review
article attempts to re-discover the field of bone formation by induction, identifying some
key features that may have been missed. These include a detailed library of all proteins
in bones and their arrangement in the 3D superstructure of the bone together with
some other important criteria not considered by tissue engineering scientists. The review
therefore not only re-iterates possible avenues of research that need to be re-explored but
also seeks to guide present and future scientists in how they assess their own research
in light of experimental design and results. By addressing these issues bone formation
by induction without autografts might finally become clinically viable.
Keywords: bone induction, biomaterials, gene and protein expression, compositional requirements, animal to
human translation, bone grafting, enigma
INTRODUCTION
“An individual unwilling to change is doomed” (Albert Einstein). Indeed much of science is based
upon the principle of change and adaptation with theories and paradigms prone to change and
alterations until complete perfection, a scientific unlikelihood, is attained. It is this basis that has
ensured that science and society as a whole has reached the technological standard that is so
Klar The Translation Enigma
common in modern day life. However, before change is accepted
it takes decades if not centuries, as adapting current philosophies
remains difficult. Yet, without the necessary stimulus current
processes cannot attain the necessary quality to become beneficial
or useful and indeed the prospect of inducing bone formation
finally in humans is no different.
The paradigm of bone induction has come a long way. But
still this form of tissue regeneration is in its infancy. It may seem
like the field has progressed far but in reality prosthetics is more
advanced than any present form of regenerative tissue science.
After more than a century clinical bone repair and regenerative
procedures still rely on the autogenous bone graft, discovered
by Havers (1692), Ollier (1867), and Senn (1889). Whilst some
progress has been made in our understanding of the molecular
mechanisms and how bone formation can be induced (Huggins,
1931; Levander, 1938; Lacroix, 1945; Urist, 1965; Ripamonti,
1990, 1991;Wang et al., 1990; Reddi, 1994, 2000; Ripamonti et al.,
1997, 2000, 2008; Klar et al., 2014) including the requirements to
induce bone formation via the soluble and insoluble combination
paradigm (Sampath and Reddi, 1981), it still remains a vision
to successfully induce, form and attain the extent of new bone
formation similar to that of an autograft. The question one must
therefore ask is what has been missed?
As science bases itself on constantly adapting its principles,
it may be time to tackle the problem of the non-bone-inductive
clinical scenario in a different manner. To do this the literature
over the last century was re-assessed, looking at key discoveries
and present research to determine criteria that have either
been ignored or still need to be answered that so far have
not been considered yet. Only the most important material
was selected and drawn upon to design possible scenarios with
relevant answers that the author of this article strongly believes
are in his opinion the solutions that could finally answer the
translation enigma from animal to human and bone induction
in medicine as a whole. But much like Einstein gravitational
theory, proven by Eddington (1920), these hypotheses/theories
inevitably relies on the support of the scientific community to
accept and prove their validity. If not, bone regenerative science
in a clinical setting will remain but an intention instead of
becoming a viable clinically applicable and acceptable process in
medicine.
OSTEOGENESIS AND REMODELING
Bone, a hard and rigid constituent of the skeleton of vertebrates
is composed primarily of calcium salts and connective tissue.
Osteogenesis, or bone formation, is the process by which new
bone is formed. There are two major modes of bone formation.
The conversion of mesenchymal tissue, during embryogenesis,
into bone is termed intramembranous ossification (Gilbert,
2000). This process occurs primarily in the bones of the skull
and some parts of the face. On the other hand endochondral
ossification, a process by which most other skeletal bones are
formed, involves first the formation of a cartilage intermediate
that is then converted into bone by bone forming cells—
osteoblasts (Gilbert, 2000).
Once bone has fully developed the only mode to generate new
bone is via the remodeling or regeneration cycle. This fascinating
and continuous process becomes active once neonatal life
commences and remains metabolically operational until the end
of the vertebrate’s existence. The bone remodeling cycle was first
described by Eriksen (1986) and involves a series of specialized
cellular events. The mesenchymal osteoblastic lineage and the
hematopoietic osteoclastic lineage are the two major constituents
necessary for proper bone regeneration (Raisz, 1999). As such,
resorption and formation exist within a balanced homeostatic
equilibrium, in which timeworn bone is continuously replaced
by new osteogenic material, helping to not just maintain the
integrity and health of bone but also permit bone to adjust
to mechanical loads and strains (Frost, 1990). Though there is
still much debate on what exactly initiates the remodeling cycle,
calcium ion dissociation from the bone matrix (Boyle et al.,
2003; Caudarella et al., 2011; Hwang and Putney, 2011; Boyce
et al., 2012; Klar et al., 2013) and bone initiatory growth factor
release via osteocytes (Hadjidakis and Androulakis, 2006) within
the bone have been suggested to be key events linked to the
bone regeneration process. However, how they interact and the
chronological order that is followed as the signals interact with
each other still remains unclear.
Osteoclasts and osteoblasts closely cooperate with each other
in the remodeling process in what is called the basic multicellular
unit (BMU) (Hadjidakis and Androulakis, 2006). The BMUs are
organized differently throughout cortical and trabecular bone.
Within the cortical bone the BMU cuts a cylindrical canal of
approximately 2,000µm in length and 150–200µm in width
within the bone, at an estimated rate of 20µm per day. This
means that during 24 h, ∼10 osteoclasts can excavate a circular
tunnel (Petrýl et al., 1996), which is filled in with new bone
via several thousands of osteoblasts (Parfitt, 1994). Thus per
annum about 2–5% of cortical bone is remodeled. In contrast
to this, trabecular bone is more actively remodeled than cortical
bone. For trabecular bone the surface to volume percentage is
much greater (Hadjidakis and Androulakis, 2006). This means
that osteoclasts are capable of moving across the trabecular bone
surface at speeds of nearly 25µm per day, excavating concavity
like trenches at an approximate depth of 55µm (Hadjidakis and
Androulakis, 2006) allowing bone remodeling to occur efficiently
and effectively within a relative small amount of time.
The remodeling cycle consists of three main consecutive
phases: Resorption, reversal and formation. In the first stage
of remodeling/bone regeneration, partially differentiated pre-
osteoclasts migrate to the surface of the bone directed there
either by calcium ion release (Boyle et al., 2003; Caudarella et al.,
2011; Hwang and Putney, 2011; Boyce et al., 2012; Klar et al.,
2014) or growth factor stimuli released by dormant osteocytes
(Hadjidakis and Androulakis, 2006). Pre-osteoclasts complete
their transition into multinucleated giant cells and attach to the
bone surface that is to be resorbed. An acidic pH is created in
the zone of resorption by the osteoclasts which secrete hydrogen
ions together with lysosomal enzymes, primarily cathepsin K.
This acidic environment ensures that all of the components
that make up the bone matrix are dissolved (Väänänen et al.,
2000). The resorption process by osteoclasts produces irregular
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scalloped cavities on the bone surface, which are referred to as
Howship lacunae, or cylindrical Haversian canals in the cortical
bone (Gilbert, 2000; Hadjidakis and Androulakis, 2006). After
the completion of osteoclastic resorption, the reversal phase
is entered. Osteoclasts enter apoptosis and mononuclear cells
appear on the bone surface. These cells polish the surface of
the resorbed area by stimulating further degradation of the
collagenmatrix within bone. Various proteoglycans are deposited
onto the surface to form a cement line whilst at the same
time releasing and depositing growth factors such as BMPs and
transforming growth factor-β (TGF-β) isoforms (Parfitt, 1994;
Gilbert, 2000; Ripamonti et al., 2010), which together help initiate
the differentiation and proliferation of osteoblasts that deposit
new osteoid at the site of the osteoclastic cut concavities (Chen
et al., 2012). In the final formation phase osteoblasts, which
have differentiated from their mesenchymal precursors, deposit
osteoid that is then transformed into mineralised bone until the
concavity has been repaired. Once this stage has been completed
the surface of the site of new bone within pre-existing bone is
covered with a flattened lining of cells and a prolonged quiescent
phase begins until the regeneration cycle is re-initiated (Parfitt,
1994; Gilbert, 2000).
This unique feature of bone, capable of revitalizing itself, has
fascinated scientists for centuries. It is this one aspect, which
has led to the development of bone regenerative medicine and
the exploration to decipher this mechanism, such that damaged
tissue can be repaired or completely regenerated.
BONE AUTOGRAFTING
As early as 2630–2611BC the father of medicine, Imhotep,
described in the Edwin Smith Papyrus, that bone was able to
repair itself when damaged (Shehata, 2004). Later Hippocrates
(460–370BC) would add to this initial finding in discovering that
bone was capable of regenerating itself with no apparent scaring
(Lanza and Vegetti, 1971). These two fundamental discoveries
provided the foundations for the emergence of two important
scientific fields, i.e., that of tissue regeneration and subsequently
the emergence of biomaterial science.
The concept of using bone grafting arose from Havers
(1692), who deciphered the inner structures of bone, especially
the vascularization of the periosteum. Havers (1692) research
permitted other medical specialist to develop techniques in
which vertebrate bone, exogenous or endogenous, can be
utilized to repair a defect within a damaged area of the
skeleton.
Pioneering bone grafts where first performed by Ollier (1867).
Ollier conducted a great deal of research on how bone grows and
was the first to suggest that a possible way to regenerate bone
was to stimulate a patients own cartilage to ossify (Ollier, 1867).
Further pioneers to use bone grafting techniques, especially
within humans would be Sir William Macewen (1848–1924) and
Sir Robert Jones (1855–1924) (Khatiwada, 2012).
Bone grafting is defined as the transplantation of bone from
one site to another (Kaveh et al., 2010). Various bone grafting
procedures exits but the golden standard of bone grafting and
bone regeneration is the autogenous bone graft technique. The
autogenous bone graft involves the harvesting of bone, from
an individual, and transplanting it within a skeletal site of
the same individual (Fox, 1984; Bauer and Muschler, 2000;
Zamprogno, 2004). It is deemed the golden standard of bone
grafting as it possess key characteristics that whilst known are
not considered in their totality when it comes to replicating
this during bone induction. Autogenous bone grafts are known
to be successful because they contain the highest number of
viable osteoprogenitor cells, are comprised of non-collagenous
matrix proteins and growth factors that are osteoinductive.
Furthermore, the autogenous bone carries with it bone mineral
and collagen which provide the foundation for the means for
proper osteoconduction (Ladd and Pliam, 1999; Keating and
McQueen, 2001; Betz, 2002; Linovitz and Peppers, 2002). Once
the autogenous bone graft is transplanted it is incorporated
quickly as it is completely biocompatible, within the grafting
site and causes a minimal immunological response, which
leads to faster healing and recovery (Samartzis et al., 2005).
However, there are limitations regarding the autogenous bone
grafting.
Depending on where the initial bone is harvested from, in the
autogenous graft procedure, various complications are known to
develop which can compromise the health of the patient. Minor
complications that have been reported are persistent donor-site
pain (Summers and Eisenstein, 1989; Goulet et al., 1997; Schnee
et al., 1997; Ebraheim et al., 2001), superficial injury of nerves
(Smith et al., 1984), the formation of hematomas or seromas
(Arrington et al., 1996; Westrich et al., 2001) and infection
(Banwart et al., 1995; Arrington et al., 1996; Westrich et al.,
2001). Major complications that can arise when using autograft
protocols are the formation of deep hematomas, which lead to
deep infections (Banwart et al., 1995; Arrington et al., 1996;
Goulet et al., 1997; Sasso et al., 1998) and necrosis of harvest site
when a large graft is utilized for transplantation (Barth, 1893).
These issues arising from autografting and other bone graft
procedures forced medicine with the help of science to try
and find alternatives to these techniques and were thus the
cornerstones that lead to the field of tissue induction and bone
engineering.
THE HISTORY OF BONE INDUCTION:
DISCOVERIES AND DEVELOPMENTS
Induction can be defined as an act that sets in motion some
course of events. In terms of osteogenesis the “induction” process
is defined as setting into motion the events of bone formation
within tissue sites not associated with the bone formation
event, i.e., muscle tissue not in the vicinity of skeletal bone or
organs.
Bone tissue engineering and regeneration has a rich
history (Urist, 1965; Reddi, 2000; Ripamonti, 2006). However,
foundations are critical as all developed theories, principles,
experiments and paradigms bear their origin from some
foundation. An incomplete foundation is most often the cause
why applications do not translate (Klar, 2011). As such only
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the most critical advances are described here as all principles
in the bone induction are derived from them but they are the
key that has shaped the field and predestined all other research,
to follow in the excitement, thereby negating critical systematic
steps crucial for science to generate answers, critical for medicine
to develop treatments from.
The earliest historical innovative record came from the
principle discovery of Senn (1889) nearly two centuries ago.
This perhaps is the most prominent discovery from which all
future bone induction research emanates from. By utilizing
decalcified antiseptic bone Senn (1889) performed a series of
implantations into skull defects of canines. Subsequently, to
his observations that these devices could stimulate new bone
formation, later to be phrased as induction (Levander, 1945),
he also serendipitously discovered that an embryonic-like tissue
often surrounded the implanted decalcified bone matrix. This
unique discovery by Senn (1889) indirectly already suggested
that the formation of new bone into these devices was the
recapitulation of osteogenesis as it occurred during embryonic
development (Levander, 1938).
Though one can dispute that Senn’s (1889) work was not
truly inductive as he implanted devices into bony sites, Huggins
(1931) uroepithelial bone induction studies showed that bone
formation could be “induced” within non-bony or heterotopic
extraskeletal sites. Later Levander (Levander, 1938; Levander and
Willestaedt, 1946) showed that partially extracted ethanol-treated
bone matrices implanted in heterotopic sites of rats could also
induced new bone formation. Levander (1945) and later again
Friedenstein (1968) suggested that there was some “substance”
that possessed bone forming capabilities, by initiating non-
mesenchymal tissue to differentiate and form new bone by either
the endochondral or membranous processes. Yet Levander’s
(Levander, 1938; Levander and Willestaedt, 1946) discovery
proved critical as he further substantiated Senn’s (1889) theory
that the induction of new bone formation in postnatal life was as a
result of the recapitulation of embryonic osteogenesis (Levander,
1938). Subsequently, Lacroix (1945) would aptly name Levander
(1938) “substance” as “osteogenin” which can be defines as a
substance or molecule that possesses the capability to induce new
bone formation.
Other discoveries of note are those of Moss (1958) who
reported on the osteogenic inductor in bone and Trueta (1963)
who discerned that angiogenesis was linked to successfully
achieving new osteogenesis. However, it would be the deductive
and pioneering work of Urist (1965), who discerned from the
pervious works of Senn, Huggins, Levander, Lacroix, Moss, and
Trueta together with his own visionary work, the foundations
and principles of bone induction (Urist, 1965; Urist et al., 1967).
However, as critical as the discoveries may have been they are
also indications as to why the induction of bone formation
still does not sufficiently form adequate bone in humans. As
visionary as Urist may have been, why he believed that only a
single molecule or family of molecules initiated or induced bone
formation remains a mystery.
In a series of heterotopic intramuscular implantations,
using allogeneic demineralized bone matrix, with the rodent
and lagomorph models including implantations within
calvarial orthotopic defect sites, Urist described to process
of autoinduction of bone (Urist, 1965). More importantly,
he discerned that there was a “bone morphogenetic protein”
complex present within the matrix of the bone that initiated
the creation of new bone or as he more commonly referred
to it bone morphogenesis. The subsequent experiments in
other animals models including Homo sapiens finally led to the
development and description of a new family of protein members
specifically referred to as “bone morphogenetic proteins (BMPs)”
(Urist et al., 1967; Urist and Strates, 1971), which were later
extracted and cloned by Wang et al. (1988) and Wozney et al.
(1988).
Subsequently, Friedenstein (1968) presented findings which
showed that certain organs could also be forced into a bone
inductive lineage. By transplanting into heterotopic sites, creating
surgical lesions in the wall or ligating the renal arteries of urinary
bladders this organ could bemade to ossify. This further extended
the idea of the BMPs being present throughout the various animal
tissues, performing different functions during development that
could be directed to form new bone, provided certain conditions
were met. This work would further contribute to another major
discovery, which was the development of the “bone induction
principle” (Urist et al., 1967).
With the successful extraction of the BMPs from the
extracellular matrix (Reddi and Huggins, 1972; Sampath and
Reddi, 1981; Reddi, 1994) a further essential step to achieving
the successful induction of bone formation was the discovery
that only an extracellular matrix with their morphogens reservoir
could induce new bone formation (Sampath and Reddi, 1981).
The bone induction principle as it would become known,
stipulated that an insoluble matrix carrier and soluble molecular
signals in the form of morphogens were required in union to
achieve the successful induction of new bone in vivo (Sampath
and Reddi, 1981). Indeed experimentation in which Sampath
and Reddi (1981) dissociatively separated the soluble molecular
signals from the insoluble collagenous matrix of demineralized
bone, by using chaotropic agents specifically guanidinium
hydrochloride and/or urea, neither of the two components
separately induced new bone formation heterotopically (Sampath
and Reddi, 1981). Only when both components were recombined
was the inductive potential restored. Though this provided a
reproducible experimental way to test various morphogens for
their inductive potential, and indicated that bone was in part a
reservoir for BMPs, it is curious why it was assumed that it was
the presence of BMPs that induced the bone formation when
in fact bone is comprised of more than just BMPs (Klar, 2011).
Instead of identifying the total chemical composition, structural
and signaling proteins including the various elements present
in bone, research was committed to isolating, sequence and
clone out BMPs, which were further revealed to be a sub-group
of a larger supergene family, i.e., the TGF-β supergene family)
(Wang et al., 1988; Wozney et al., 1988; Özkaynak et al., 1990;
Reddi, 2000; Ripamonti et al., 2004; Ripamonti, 2006) which
are considered the best protein group of inducing new bone
formation (Kaur et al., 2016).
Since then, the vast majority of experimental research has
tried to clinically induce bone formation in man, which though
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successful in various animal models, has unfortunately not yet
come close to replacing the golden standard for bone tissue
regeneration, the bone autograft. Perhaps the solution lies at
determining how bone induction functions mechanistically at
the gene and protein expression level. On the other hand,
there may be a gap in information related to the structural
and signaling milieu of proteins and other elements that
make up bone which have yet to be fully elucidated and
interpreted.
BIOMATERIALS
Biomaterials are defined as synthetic or natural materials that
are suitable for utilization in constructing artificial organs or
prostheses. Biomaterials can be derived either from nature or by
synthetic using a variety of chemical approaches. They are often
used and/or adapted for a medical application, and thus comprise
whole or part of a living structure or biomedical devices which
performs, augments, or replaces a natural function. Functionmay
be benign, such as being used for regenerating a bone segment or
may be more bioactive with a more interactive functionality such
as hydroxyapatite coated hip implants.
Biomaterials are generally formed by self-assembly. Self-
assembly is the most common term used to describe the
spontaneous aggregation of particles, without the influence of
any external force. Large groups of such particles are known to
assemble themselves into thermodynamically stable, structurally
well-defined arrays. Molecular self-assembly is found primarily
in biological systems and provides the basis for a wide variety of
complex biological structures. It is these self-assembled biological
structures which are most sought in biomaterials and how to
replicate their design since naturally derived composites to date
are still the most efficient when it comes to stimulating, initiating
or inducing regenerative processes. Though more than 190
different biomaterials exist to date, only a few can induce bone
formation via spontaneity; some of which are coralline derived
devices (Weber et al., 1971; Chiroff et al., 1975; White et al., 1975;
Ripamonti, 1990, 1991).
Corals share a somewhat similar structural, physical and
chemical characteristic as that of bone. This trait was first
observed by Chiroff et al. (1975). Members of the Porites
and Goniopora species both belonging to the Poratidae family
of corals, are the best suited at designing coralline calcium
phosphate/hydroxyapatite bone substitutes (Chiroff et al., 1975).
These corals are effective in promoting bone development within
their spaces/pores as the pore sizes, between 200 and 500µm
in diameter, are effective in directing cellular migration and
subsequent differentiation of cells associated with the bone
formation process. But before corals are able to do so they have to
undergo hydrothermal exchange (Roy and Linnehan, 1974) and
morphological alterations by replamineformation (White et al.,
1975). In the hydrothermal exchange process, coral exoskeletons
and phosphate are added in equal quantities to water (Roy and
Linnehan, 1974). Under extreme heat and pressure the carbonate
ions within the exoskeleton of the coral (calcium carbonate—
CaCO3) are substituted by phosphate, producing hydroxyapatite
(calcium phosphate—CaPO4). Varying the amount of phosphate
or time taken for the exchange to occur can yield varying
conversion, i.e., partial conversion of calcium carbonate to
hydroxyapatite, to complete conversion of calcium carbonate
to hydroxyapatite. This greatly affects bone formation within
the coral derived biomimetic device. Once the hydrothermal
exchange has been completed the coral is replamineformed
(White et al., 1975), whereby the surface morphology is altered
such that the device takes on the shape and structure of bone
which can vary anything frommandibular, cranial or long bones,
hence mimicking skeletal structures.
Though there are a various substitutes that have been tested
as alternatives to bone grafts, none have been more successful
at inducing bone formation than coral-derived macroporous
devices (Ripamonti, 1990, 1991). Corals have been shown to
be of clinical significance. Not only do coral derived devices
act similarly to bone grafts used in filling up bone voids
resulting from articular surface depressions in tibial plateau
fractures (Bucholz et al., 1989) but they are also one of the
only biomaterials able to spontaneously induce bone formation
without the application of exogenous growth factors (Ripamonti,
1990, 1991; Ripamonti et al., 2010; Klar et al., 2013) and next
to the 190+ different biomaterials currently available, with
considerable more being added yearly, corals remain to date, in
this authors opinion, the best and only viable source of possible
bone inductive biomaterial, as it is both osteoconductive and
inductive, requires no morphogens to induce bone formation
at the site of implantation, irrespective of the defect size, and
IF the correct morphogen could be found then the solution to
healing bone defects comes that much closer to reality. However,
history has shown that even with such good qualities and
capabilities something is being missed, with supraphysiological
doses of morphogens not being a viable alleviation to the
problem.
TGF-β SUPERFAMILY MEMBERS AND
BONE FORMATION
The work of Wozney et al. (1988) permitted the molecular
cloning of several BMPs/OPs, which were found to be members
of the TGF-β supergene family. Proteins were firstly isolated
after chromatographic purification methods (Urist et al., 1984;
Sampath et al., 1987; Wang et al., 1988; Luyten et al., 1989).
Amino acid sequence motifs from batches of purified proteins
were then used for molecular cloning of an entirely new family
of proteins initiators, collectively called the BMPs (Wozney et al.,
1988; Celeste et al., 1990; Özkaynak et al., 1990; Hammonds
et al., 1991; Sampath et al., 1992). We have since then learned
that BMPs are a family of highly conserved secreted pleitropic
proteins that intiate cartilage and bone formation in vivo
(Wozney et al., 1988; Sampath et al., 1992; Reddi, 2000;
Ripamonti et al., 2004; Ripamonti, 2006).
BMPs have been shown to be involved in pattern formation
during embryonic organogenesis (Reddi, 2005). A remarkable
characteristic of BMPs gene products is that when implanted
heterotopically in animal models they can induce new
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endochondral bone formation (Reddi, 2000; Ripamonti et al.,
2004; Ripamonti, 2006).
BONE MORPHOGENETIC PROTEINS
Development, embryogenesis, pattern formation and organo-
and skeletogenesis require the action of BMPs (Alliston and
Derynck, 2000; Alliston et al., 2008). BMP signaling is regulated
via their localized expression, the action of specific antagonists
and a series of negative and positive feedback loops (Alliston and
Derynck, 2000; Alliston et al., 2008). During skeletal development
BMP-2 to -7 have an overlapping pattern of expression to
ensure development occurs in an ordered manner (Solloway
et al., 1998). Whilst BMP receptors type II and type I alpha
(BMPRII and BMPRIA), like most members of the TGF-β
family, are ubiquitously expressed (Kawabata et al., 1995), BMPR
type I beta (BMPRIB), as shown by Ishidou et al. (1995),
is principally transcribed only within developing bone and
cartilage. Only when bone, in adult life, is damaged are all BMP
receptors expressed (Onishi et al., 1998), as they facilitate part
of the activation of the bone regeneration cycle. Subsequently,
further research studies by Rickard et al. (1998), Mundy et al.
(1999) and Rawadi et al. (2003) has shown that additional
proteins, specifically statins, estrogen and wingless-type MMTV
integration site family member 3A (Wnt3a), are also capable of
activating the BMPs.
The activities of the BMPs are highly regulated by a series of
antagonists and agonists. Chordin, Follistatin, Gremlin, Noggin
and Sclerostin are specific antagonists known to inhibit the
BMP pathway activation and thus bone formation (Alliston
and Derynck, 2000; Alliston et al., 2008). Research studies have
revealed BMPs are also capable of activating the expression of
their inhibitors including Noggin and the intracellular BMP
pathway inhibitory Smad family members 6 and 7 (Smad6 and
Smad7) (Gazzerro et al., 1998; Takase et al., 1998; Ishisaki et al.,
1999; Pereira et al., 2000; van Bezooijen et al., 2005). Additionally,
members of the entire BMP signaling pathway, including their
initiators and antagonist are subjected to further regulation by
a series of positive and negative feedback signaling loops that
interact with other signaling pathways (Alliston and Derynck,
2000; Alliston et al., 2008).
BMP signaling commences when a BMP ligand binds first to
either the BMPR1A or BMPRIB, after which it forms a receptor
complex with BMPRII, i.e., BMPRIA/B + BMPRII (Berk et al.,
1997; Hayashi et al., 1997; Imamura et al., 1997; Yoshida et al.,
2000; Sowa et al., 2004). This active complex then activates
the Smad transcription receptor complex to regulate nuclear
transcription factor activity (Berk et al., 1997; Hayashi et al., 1997;
Imamura et al., 1997; Yoshida et al., 2000; Sowa et al., 2004). It is
this spatial and temporal regulation of the various components of
the BMP pathway that ensure proper skeleto-and organogenesis
during embryo development as well as the maintenance of bone,
later in postnatal life (Alliston and Derynck, 2000; Alliston et al.,
2008).
Storm et al. (1994) revealed that growth differentiation
factor (GDF)-5, -6, and -7, also referred to as cartilage-derived
morphogenetic proteins (CDMP-1, -2, and -3) (Chang et al.,
1994; Storm et al., 1994) are involved in bone formation and
development in vivo (Mikic et al., 2002). GDF-5 to -7 have been
found, via gene knocked studies, to control the length of long
bone formation in limbs and regulate patterning of segments in
the digits, chondrogenesis and longitudinal bone growth (Storm
et al., 1994; Storm andKingsley, 1996, 1999). GDFs have also been
shown to induce osteogenic differentiation within in vitro stem
cell differentiation studies (Erlacher et al., 1998; Yeh et al., 2005).
In term of bone formation by induction, the first of the BMPs
to be used in induction studies was the recombinant human
BMP-2 (rhBMP-2). In a time study, conducted by Wang et al.
(1990), rhBMP-2 increased the rate of cellular invasion and
induced chondrogenesis within the demineralized bone matrices
after just 5 days. Within 7 days the cartilage was beginning to be
ossified and after just 21 days the bone matrix had been ossified.
These findings thus established that BMP-2 was one of the signals
essential at initiating bone formation, be it within biomaterials
or native bone regeneration respectively. Subsequently other
BMPs were tested for their role in inducing bone formation.
BMP-4 induces bone formation but only when used at high
concentration (Hammonds et al., 1991), with BMP-5 inducing
bone at a reduced rate, irrelevant of application dose (Cox et al.,
1991; D’Alessandro et al., 1991). Subsequently BMP-6, osteogenic
protein-1 (OP-1/BMP-7) and BMP-9 all are known to induce
bone formation similar to that of BMP-2 (Riley et al., 1996). With
such a substantial background of BMPs being an osteoinductive
factor both in animal models and within subsequent clinical trials
(Boden et al., 2002) it was postulated that bone formation was
initiated and modulated only by the BMPs and their signaling
pathway, since osteoinductive experiments before 1997 testing
TGF-β isoforms, in rodents and lagomorphs, failed to induce
bone formation (Roberts et al., 1986).
TRANSFORMING GROWTH FACTOR-β
ISOFORMS
The three mammalian TGF-β isoforms, TGF-β1, TGF-β2, and
TGF-β3 signal through receptor complexes of the TGF-β
type II receptor (TßRII) and TßRI (Alliston et al., 2008).
In vitro research has shown that although each of the TGF-
β isoforms functions similarly at the cellular level (Alliston
et al., 2008) their contribution within embryonic osteogenesis
is quite different (Alliston et al., 2008). In knockout studies,
during murine development, each corresponding gene produces
unique phenotypic deviations, which reflect the TGF-β isoforms
different spatio-temporal distributions and roles. The silencing
of TGF-β1 results in abnormal bone quality (Shull et al., 1992;
Kulkarni et al., 1993), whereas deletions of TGF-β2 or TGF-
β3 impaires epithelial-mesenchymal trans-differentiation, cyto-
proliferation and palate formation of the skull (Kaartinen et al.,
1995; Proetzel et al., 1995; Sandford et al., 1997).
During bone formation in skeletogenesis, the expression
patterns from various TGF-β isoforms are further modulated
by a series of positive and negative feedback loops (Alliston
et al., 2008), including the various inhibitors. However, there are
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apparent differences between the mRNA and protein expression
patterns, which regulate TGF-β isoform storage in cartilage
and bone (Alliston and Derynck, 2000). Pelton et al. (1991)
indicated that the extracellular matrix proteins from bone
interact with certain of TGF-β isoforms, particularly TGF-β1,
allowing them to be deposited within bone. In the mesenchyme,
all TGF-β isoforms are expressed which is increased as the
mesenchyme condenses in preparation for osteogenesis (Alliston
et al., 2008). Experimental research has revealed that whilst
TGF-β3 is expressed during the early development of cartilage
formation, TGF-β1 and TGF-β2 expression is hardly transcribed
(Pelton et al., 1990, 1991). As osteogenesis matures, TGF-β3 levels
diminish, whereas TGF-β1 and TGF-β2 levels increase (Pelton
et al., 1990). Primarily it seems that TGF-β3 levels are highest
in tissues associated with skeletogenesis and bone formation,
whereas TGF-β2 more likely to be transcribed at sites of where
new bone mineralization occurs (Alliston et al., 2008).
In previous research studies of mouse cartilage, TGF-β3
expression is higher than in relation to the other TGF-β isoforms
(Pelton et al., 1990, 1991). Subsequently other research studies
on the mouse growth plate have found that whilst TGF-β2 is
transcribed throughout all the regions of the developing plate,
TGF-β1 and TGF-β3 are restricted to only the hypertrophic
and proliferative areas (Sandberg et al., 1988; Millan et al.,
1991; Thorp et al., 1992; Horner et al., 1998). The periosteums
of endochondral and intra-membranous bones shows high
levels of expression of TGF-β1 and TGF-β2 respectively, whilst
osteoclasts and osteoblast show varied expression patterns in
TGF-β isoforms (Pelton et al., 1991).
In developing bones the TβRI and TβRII are transcribed
throughout the developing embryonic skeleton (Horner et al.,
1998), but in hypertrophic chondrocytes and mineralized
osteophyte tissue their expression is reduced and lost,
respectively (Horner et al., 1998). The Smads, known regulators
of the TGF-β pathway, are also subject to regulation in skeletal
tissue (Sakou et al., 1999). In vitro cell culture experiments
Smad2, Smad3, and Smad4 including the inhibitory Smad6 and 7
are all differentially expressed within proliferating chondrocytes
and bone cells (Sakou et al., 1999; Alliston et al., 2008).
Inactivation and storage of TGF-β isoforms is facilitated by
latent TGF-β-binding proteins (LTBPs) (Shipley et al., 2000),
where all four isoforms of LTBPs-(1-4), except for LTBP-
2 associate with the TGF-β isoforms (Shipley et al., 2000).
Although all four LTBPs are broadly expressed and regulated,
LPBT-3 expression is the highest in bone, whereas LTBP-2
has been detected to be principally expressed in chondrogenic
condensations (Shipley et al., 2000). Although other studies have
shown that there are ways in which the formation and storage of
TGF-β complexes can be regulated (Oreffo et al., 1989; Oursler,
1994; Dallas et al., 2002; Kwok et al., 2005), bone formation by the
LTBPs isoforms is considered to be the primary mode by which
skeletal bone is developed.
With respect to bone formation by induction, TGF-β isoforms
were shown in well-established animal models, such as the rat,
to be non-osteoinductive (Roberts et al., 1986), instead tending
to form endothelial or vascular tissue. However, when TGF-β1
was loaded within a collagen-matrix carrier and implanted within
heterotopic extraskeletal muscle sites of the rectus abdominis
muscle, of Papio ursinus (Chacma baboon), bone formation was
induced (Ripamonti et al., 1997). In a series of systematic studies,
in this new animal model, Ripamonti et al. (2000, 2008) showed
that the principle concept of BMP induced bone formation to be
flawed, by showing that also TGF-β2 and especially TGF-β3 could
induce bone formation with biomimetic devices in these animals.
Naturally this theory has since then been further adapted,
as more recent studies in non-human primates and monitoring
the gene expression over a period of 90 days has revealed that
the supposed induction of bone formation by TGF-β3 in fact is
not direct but regulatory. The TGF-β3 isoform seems to act as
a major regulator, a suggested signaling control center, which
regulates BMP signaling by down regulating inhibitory BMP
signals (Klar et al., 2014). Thus rather than directly affecting
the induction process within a heterotopic implantation model,
the TGF-β3 isoformmodulates specialized molecular and cellular
cues and therefore can indirectly initiate the induction process by
allowing the over-expression of BMPs to occur, resulting in not
just increased induction rates but also quicker formation of bone
through heightened cellular differentiation and proliferation
(Klar et al., 2014). Subsequently, and more interesting, is the
fact that the signals of the TGF-β isoform family evolved or
mutated somewhere, between rats and primates as the effect of
TGF-β isoforms seems to behave differently between these two
species (Ripamonti et al., 2016). This suggests that homogeneity
principles applied between animal models and humans must
also be inconsistent, which are indeed supported by the in-
translatability of bone studies from animals into humans. Could
this be part of the problem and solution or does this mean that
indeed all proteins, whilst inherently similar in structure function
differently the higher one goes in evolution? The issue remains
that of clinical translatability, where neither BMPs/OPs nor TGF-
β isoforms have shown any significant impact similar or better
than the autogenous bone graft.
THE ANIMAL TRANSLATION ENIGMA
Evidence has always indicated that in vitro to in vivo testing and
subsequently in vivo to human trials do not properly replicate
treatments within a clinical setting (Denayer et al., 2014). This
suggests that key factors are not considered in attempts to
translate animal experimentation principles into a clinical setting.
Major areas of concern are those of pathophysiology,
methodological design and sample size variations which are often
ignored when translating into the clinical aspect, whilst others
are limited to the extent of ethical concerns when experimenting
on humans. In their review Denayer et al. (2014) adequately list
critical determinants when it comes to translating to a human
model. Evans (2016) also highlights criteria such as maturity of
animals, scale-up from animal models to humans and differences
between bones, i.e., cranial vs. femur. Alternatively, it has to be
considered that present bone induction procedures are utilizing
allo-and xenografting principles, that have been shown to not
function in vivo (Ladd and Pliam, 1999; Keating and McQueen,
2001; Betz, 2002; Linovitz and Peppers, 2002), but are replicated
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in the form of biomaterials, utilizing autogenous bone grafting
principles.
Another critical mistake is that most studies overlook
the difference between animal and human genes that, whilst
structurally similar, have different expression patterns or
function. Often it is assumed that animal models, in particular
for inductive bone studies, are genetically compatible to each
other since osteogenesis appears to be similar between all
experimentally utilized animal models compared to humans.
Whilst there are homologous trends in the gene structure
of various animal models, with that of the human including
functionality in vivo, a fact often left out is that in most cases
subtle variations in gene structure can produce considerable
difference between species. The research of Ripamonti et al.
(1997, 2000, 2008, 2016) and TGF-β isoforms only inducing
bone formation in non-human primates opposed to other animal
models (Roberts et al., 1986), clearly reiterates this. However
the main causes for these conflicting results are perhaps related
more to the trend of not presenting unexpected results, together
with the use of outdated methods. A good example here would
be quantitative real-time reverse transcription polymerase chain
reaction (qRT-PCR).
qRT-PCR has become the leading analytic technique which
over the last two decade has made considerable progress (Mullis,
1990; Higuchi et al., 1993; Bustin, 2000, 2002; Vandesompele
et al., 2002; Bustin and Nolan, 2004; Bustin et al., 2009, 2010,
2013; Vermeulen et al., 2011) at improving the accuracy of
gene expression data. Whilst some bone and cartilage research
groups have already utilized the new standards as set out by
Bustin et al. (2009) pioneering “Minimum Information for
Publication of Quantitative Real-Time PCR Experiments (MIQE)
guidelines” (Bustin et al., 2009; Klar et al., 2013, 2014; Ripamonti
et al., 2016), a considerable number of research groups in the
bone tissue engineering field still utilize outdated and highly
insufficient qRT-PCR techniques that, when combined with
frequent insufficient experimental detail, render replication of




Though much research has been conducted into understanding
how to induce new bone formation and which growth
factors show distinctive patterns to initiate, promote, regulate
and modulate new bone formation, single dosages of these
morphogens simply do not produce the necessary amount of
bone formation required to make these procedures standard
clinical practice.
To this day few studies have attempted to deviate from this
practice. To date Ripamonti et al. (1997, 2010) has been the only
study on bone formation by induction to show that two separate
but structurally similar TGF-β supergene family members could
synergize with each other to increase bone formation quantities
in vivo compared to utilizing conventional single morphogen
applications of the same type. However, more needs to be
done. Taken in consideration with an autogenous bone graft the
following remains elusive.
First the autogenous bone graft contains a reservoir of
structural and signaling proteins; the second is that these proteins
are present at a physiological dose and in a “non-recombinant”
state. A possible reason why an autogenous bone graft works
is that it possesses complete and specific protein content. From
these are initiators, regulators, inhibitors, modulators including
all the structural molecules, arranged in a certain configuration
in the 3D superstructure of the graft which together interacts
with each other and subsequently with site to where the graft is
transplanted. The healing equilibrium is therefore maintained,
compared to being greatly limited if only a single morphogen
were present. Indeed, Wildemann et al. (2007) described this in
part, but the findings were restricted to only assessing the content
of proteins that were present at the highest concentrations. The
complete protein content of a fragment of bone from different
skeletal areas remains elusive.
Another determining factor, aside from the types of proteins,
is the exact protein quantity of each protein within a fragment
of bone. At the incorrect dosage, BMPs and TGF-βs in the
bone induction have been shown to stimulate the formation of
tumors and cancers (Riemenschneider et al., 2015; Skovrlj et al.,
2015). Zara et al. (2011) has shown that the correct amounts
of protein-induced bone formation exist at significantly lower
levels than is currently utilized to induce new formation of bone
within in vivo and clinical models. Subsequently, all forms of
proteins utilized in the scientific bone tissue engineering field
are recombinant proteins, which are not the same structure as
found natively within the bone matrix. Recombinant human
BMP-2, for example, is a dimeric protein whereas in its native
form is a heterodimer (Israel et al., 1996; Evans, 2016). It is
suggested that the heterodimer functions differently at inducing
bone formation than the recombinant molecule where the
heterodimeric structure resists total inhibition by modulators,
such as Noggin (Song et al., 2010) to permit for more
regulated bone formation. The autograft as such could be
working because the amounts and correct protein structures are
available in a configuration suitable for the natural physiological
program to decode, supporting the physiological response,




Whilst many relevant concepts and theories exist, their
implementation into a clinical scenario is based on how
accurate results are, irrelevant of the type of synthetic induction
model considered. When Urist, Reddi, Sampath and Wozney
(Urist, 1965; Sampath and Reddi, 1981; Wozney et al., 1988)
originally started deciphering the induction of bone formation,
the technology of molecular biology was very limited. Whilst
much has been done in the field of bone tissue engineering, it
is becoming clear that fundamental core foundations need to be
re-assessed (Evans, 2016) and updated.
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In order to reverse engineer a complex system, one must take
it apart into all of its components; assess the shape and function
of these constituents, how they integrate within each other and
how each component affects their neighbors. Following this,
cloned components can be engineered synthetically with most
of the original traits and reassembled to resemble the original
system in shape and function (Chikofsky and Gross, 1990; Eldad,
2005). Overlooking one component’s design feature will lead
to misbehaving replica, meaning a revision of theories and
paradigms until parts are adequately designed and work as they
are intended to. Taken into the context of the bone formation
by induction vs. autogenous bone grafting, the problem remains
evidently complex and multi-faceted, where there are many
solutions possible too numerous to contain all within a single
review.
Critical is that future research needs to accept that as
technology improves, old paradigms need to be updated
based on previous mistakes. Specifically toward solving bone
formation by induction, in the opinion of the author, a detailed
library of all micro-and macromolecules, which include also
other molecules such as miRNAs, nano-and macro-particles,
including how these are arranged within the superstructure of
all skeletal bones, needs to be established to permit accurate
synthetic replication of the healing processes within in vivo
clinical applications. Subsequently, while current animal models
have shown us some insights, they are unreliable and are
unsuitable for developing treatments for bone tissue engineering.
There is a clear need to develop more reliable non-in vivo
models that adequately replicate the human bone environment
in vitro allowing for faster and more accurate clinically
transducable treatments to be developed. Here, bioreactors
platforms, replicating bone as an organ, are the perfect alternative
to simulate the in vivo human environment (Martin et al.,
2004; Plunkett and O’Brien, 2011), provided however that
the library of all micro- and macromolecules exists. Only by
critically re-evaluating the past in light of the future can bone
formation without autogenous bone grafting become feasible
clinically.
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